Literature DB >> 8624866

Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction.

L M Rodríguez1, E B Sternick, J L Smeets, C Timmermans, K den Dulk, G Oreto, H J Wellens.   

Abstract

OBJECTIVE: To examine the value of programmed electrical stimulation of the heart in predicting sudden death in patients receiving amiodarone to treat ventricular tachyarrhythmias after myocardial infarction.
DESIGN: Consecutive patients; retrospective study.
SETTING: Referral centre for cardiology, academic hospital. PATIENTS: 106 patients with ventricular tachycardia (n = 77) or ventricular fibrillation (n = 29) late after myocardial infarction.
INTERVENTIONS: Programmed electrical stimulation was performed while on amiodarone treatment for at least one month.
MEASUREMENTS AND MAIN RESULTS: In 80/106 patients either ventricular fibrillation (n = 15) or sustained monomorphic ventricular tachycardia (n = 65) was induced. After a mean follow up of 50 (SD 40) months (1-144), 11 patients died suddenly and two used their implantable cardioverter debfibrillator. By multivariate analysis two predictors for sudden death were found: (1) inducibility of ventricular fibrillation under amiodarone treatment (P << 0.001), and (2) a left ventricular ejection fraction of < 40% (P < 0.05). The survival rate at one, two, three, and five years was 70%, 62%, 62%, and 40% respectively for patients in whom ventricular fibrillation was induced, and 98%, 96%, 94%, 94% for patients with induced sustained monomorphic ventricular tachycardia. Where there was no sustained arrhythmia, five year survival was 100%.
CONCLUSIONS: In patients receiving amiodarone because of life threatening ventricular arrhythmias after myocardial infarction, inducibility of ventricular fibrillation, but not of sustained monomorphic ventricular tachycardia, indicates a high risk of sudden death.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8624866      PMCID: PMC484216          DOI: 10.1136/hrt.75.1.23

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  17 in total

1.  Antiarrhythmic efficacy and electrophysiologic actions of amiodarone in patients with life-threatening ventricular arrhythmias: potent suppression of spontaneously occurring tachyarrhythmias versus inconsistent abolition of induced ventricular tachycardia.

Authors:  K Nademanee; J Hendrickson; R Kannan; B N Singh
Journal:  Am Heart J       Date:  1982-06       Impact factor: 4.749

2.  Determinants of prognosis in symptomatic ventricular tachycardia or ventricular fibrillation late after myocardial infarction. The Dutch Ventricular Tachycardia Study Group of the Interuniversity Cardiology Institute of The Netherlands.

Authors:  A R Willems; J G Tijssen; F J van Capelle; J H Kingma; R N Hauer; F E Vermeulen; P Brugada; D C van Hoogenhuyze; M J Janse
Journal:  J Am Coll Cardiol       Date:  1990-09       Impact factor: 24.094

3.  Amiodarone for control of sustained ventricular tachyarrhythmia: clinical and electrophysiologic effects in 51 patients.

Authors:  H L Waxman; W C Groh; F E Marchlinski; A E Buxton; L M Sadowski; L N Horowitz; M E Josephson; J A Kastor
Journal:  Am J Cardiol       Date:  1982-11       Impact factor: 2.778

4.  Amiodarone pharmacokinetics.

Authors:  D W Holt; G T Tucker; P R Jackson; G C Storey
Journal:  Am Heart J       Date:  1983-10       Impact factor: 4.749

5.  Clinical pharmacokinetics and efficacy of amiodarone for refractory tachyarrhythmias.

Authors:  C I Haffajee; J C Love; A T Canada; L J Lesko; G Asdourian; J S Alpert
Journal:  Circulation       Date:  1983-06       Impact factor: 29.690

6.  Long-term clinical outcome of ventricular tachycardia or fibrillation treated with amiodarone.

Authors:  B McGovern; H Garan; R F Malacoff; J P DiMarco; G Grant; T D Sellers; J N Ruskin
Journal:  Am J Cardiol       Date:  1984-06-01       Impact factor: 2.778

7.  Disparity between the clinical and electrophysiologic effects of amiodarone in the treatment of recurrent ventricular tachyarrhythmias.

Authors:  A W Hamer; W B Finerman; T Peter; W J Mandel
Journal:  Am Heart J       Date:  1981-12       Impact factor: 4.749

8.  Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation.

Authors:  J J Heger; E N Prystowsky; W M Jackman; G V Naccarelli; K A Warfel; R L Rinkenberger; D P Zipes
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

9.  Usefulness of electrophysiologic testing in evaluation of amiodarone therapy for sustained ventricular tachyarrhythmias associated with coronary heart disease.

Authors:  L N Horowitz; A M Greenspan; S R Spielman; C R Webb; J Morganroth; H Rotmensch; N M Sokoloff; A P Rae; B L Segal; H R Kay
Journal:  Am J Cardiol       Date:  1985-02-01       Impact factor: 2.778

10.  The value of the clinical history to assess prognosis of patients with ventricular tachycardia or ventricular fibrillation after myocardial infarction.

Authors:  P Brugada; M Talajic; J Smeets; R Mulleneers; H J Wellens
Journal:  Eur Heart J       Date:  1989-08       Impact factor: 29.983

View more
  2 in total

Review 1.  Can antiarrhythmic agents be selected based on mechanism of action?

Authors:  W Lau; D Newman; P Dorian
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

2.  Comparative follow up of patients with implanted cardioverter-defibrillators after induction of sustained monomorphic ventricular tachycardias or ventricular fibrillation by programmed stimulation.

Authors:  M Meyborg; R Mura; C Tiefenbacher; R Becker; J Michaelsen; F Niroomand
Journal:  Heart       Date:  2003-06       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.